[Preparations of human dopamine beta hydroxylase subunits and antibodies against these subunits (author's transl)]. / Préparation des sous-unités de la dopamine beta hydroxylase humaine et des anticorps anti-sous-unités.

The present study deals with the dissociation of human dopamine beta hydroxylase (DBH) in subunits with a mol. wt of 79,500, and the preparation of specific antibodies in rabbits. No cross-reactivity was observed between human DBH and antibodies against human DBH subunits.

[Estrogen and progestogen cytosol receptors in human breast carcinoma (author's transl)]. / Etude des récepteurs cytosoliques oestrogènes et progestogènes dans les carcinomes mammaires.

The authors have studied Estrogen (RE) and Progestin (RP) cytosol receptors in 379 human breast carcinomas: 281 tumors suitable for surgery, 26 pseudo-inflammatory tumors, 52 metastases and 20 recurrences. They have used an exchange technique with estradiol for RE and a synthetic compound, R 5020, for RP. The results point out that high rates of RE correlate with post-menopausal women and high rates of RP with pre-menopausal women. Tumours are considered receptor-positive when the binding sites concentration exceeds 100 fmoles/g tissue. Using this as a base 32% of the tumors are RE and RP negative. Considering only the positive tumors, 54% contain both receptors, 31% only RE and 15% only RP. The percentages are also given in terms of the hormonal state of the patients. The results are discussed in terms of McGuire's hypothesis that both receptors are necessary to obtain a positive response to hormonal therapy. Correlation between histology and receptors is also discussed.

PIP: Estrogen (RE) and progestin (RP) cytosol receptors in 379 human breast carcinomas were studied: 281 tumors suitable for surgery, 26 pseudo-inflammatory tumors, 52 metastases, and 20 recurrences. An exchange technique with estradiol for RE and a synthetic compound, R 5020, for RP was used. The results indicate that high rates of RE correlate with postmenopausal women and high rates of RP with premenopausal women. Tumors are considered receptor-positive when the binding site concentration exceeds 100 fmoles/gm tissue. Using this as a base, 32% of the tumors are RE and RP negative. Considering only the positive tumors, 54% contain both receptors, 31% only RE, and 15% only RP. The results support McGuire's hypothesis that both receptors are necessary to obtain a positive response to hormonal therapy. However, a correlation has only been demonstrated with the effects of the hormonal treatments and the presence of the RE receptors.

[Estrogen and progresterone receptors in male breast diseases]. / Récepteurs aux estrogènes et aux progestogènes en pathologie mammaire chez l'homme.

The authors study estrogen (RE) and progestogen (RP) receptors by an exchange technique in 8 cases of male breast carcinoma and 7 cases of gynaecomastia. Tumours are considered receptor positive when the binding sites concentration exceeds 100 fmol/g tissue. Using this as a base all the carcinoma are RE+ and 7/8 are RP+. Gynecomastia are always RE- and RP- except for one case which is RP+. RE and RP levels are correlated with the degree of differentiation of the carcinoma, as determined histologically.

[Estrogen and progesterone receptors in non carcinomatous breast diseases (author's transl)]. / Récepteurs des estrogènes et de la progestérone dans les affections non carcinomateuses du sein.

Cytosolic receptors for estrogens and progesterone are studied using an exchange method in various types of benign breast diseases: fibroadenomas, fibrocystic mastosis, phylloid tumors and gynecomastias. The results show clearly that, contrary to breast carcinomas, receptors are generally not present in benign tumors. These results are statistically significant for all the women studied. Studying the pathological aspects of the tumors, it can be noted that the presence of receptors, is correlated with proliferation forms with large epithelial components. Furthermore, these results show that receptors are not found in gynecomastia. In conclusion, the physician should follow up very carefully the patients with a benign tumor, when hormono-receptors are present.

Adenosine 3',5'-cyclic monophosphate and guanosine 3',5'-cyclic monophosphate levels in human breast cancer tissue.

Intracellular levels of adenosine 3',5'-cyclic monophosphate and guanosine 3',5'-cyclic monophosphate were measured in breast carcinomas. These levels were increased significantly as compared to normal breast tissues. In benign breast tumors, intermediate levels of adenosine 3'5'-cyclic monophosphate were observed, but they did not differ significantly with malignant tissues. No relation has been shown with estradiol or progesterone binding sites.

[Perturbations of the levels of hypophyseal serotonin induced by oral administration of a single dose of 7, 12-dimethyl 1-2 benz(a)anthracene in rats].

Pituitary serotonin was estimated by fluorescence technique in rats fed with DMBA at 30 days, 60 days or 90 days age. In the rats most receptive to this carcinogen, serotonin was found to be decreased to 40% of control values, for the 8 days period studied. A possible mechanism leading to hormonal unbalance is proposed.

Dopamine-B-hydroxylase and catecholamines in an olfactory esthesioneuroma.

In a case of olfactory esthesioneuroma, of which an unfixed specimen and blood sample were available, we demonstrated immunohistochemically and biochemically the presence of dopamine-B-hydroxylase and catecholamines in low concentration. This result indicates that this nasal tumor is probably of sympathetic origin, in whole or in part, and provides a new aid in diagnosis. Furthermore, biochemical assay of dopamine, V.M.A., and H.V.A. excretion in urine could perhaps bring information of diagnostic and prognostic value before and after treatment.